Spinocerebellar ataxia type 1 (
SCA1) is an adult-onset, dominantly inherited
neurodegenerative disease caused by the expanded
polyQ tract in the
protein ATAXIN1 (ATXN1) and characterized by progressive motor and
cognitive impairments. There are no disease-modifying treatments or cures for
SCA1.
Brain-derived neurotrophic factor (
BDNF) plays important role in cerebellar physiology and has shown therapeutic potential for cerebellar pathology in the transgenic mouse model of
SCA1, ATXN1[82Q] line that overexpress mutant ATXN1 under a cerebellar Purkinje-cell-specific promoter. Here we demonstrate decreased expression of
brain derived neurotrophic factor (
BDNF) in the cerebellum and medulla of patients with
SCA1. Early stages of disease seem most amenable to
therapy. Thus, we next quantified
Bdnf expression in Atxn1154Q/2Q mice, a knock-in mouse model of
SCA1, during the early symptomatic disease stage in four clinically relevant brain regions: cerebellum, medulla, hippocampus and motor cortex. We found that during the early stages of disease,
Bdnf mRNA expression is reduced in the hippocampus and cerebellum, while it is increased in the cortex and brainstem. Importantly, we observed that pharmacological delivery of recombinant
BDNF improved motor and cognitive performance, and mitigated pathology in the cerebellum and hippocampus of Atxn1154Q/2Q mice. Our findings demonstrate brain-region specific deficiency of
BDNF in
SCA1 and show that reversal of low
BDNF levels offers the potential for meaningful treatment of motor and cognitive deficits in
SCA1.